Bianca Rocca
Overview
Explore the profile of Bianca Rocca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
3745
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tamargo J, Agewall S, Ambrosio G, Borghi C, Cerbai E, Dan G, et al.
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
PMID: 40058879
Despite substantial advances in cardiovascular pharmacotherapy and devices in recent years, prevention and treatment of many cardiovascular diseases (CVD) remain limited, thus reflecting the need for more effective and safer...
2.
Erdoes G, Milojevic M, Rocca B, Koster A
Eur J Cardiothorac Surg
. 2025 Jan;
67(2).
PMID: 39873698
No abstract available.
3.
Tafciu E, Pilan M, Rocca B, Minnucci I, Maffeis C, Bergamini C, et al.
Am J Cardiol
. 2025 Jan;
241():1-8.
PMID: 39788403
Tricuspid regurgitation (TR) is related to survival, and right atrial (RA) size and function may play a role. This study aimed to assess the impact of RA function measured by...
4.
Petrucci G, Rizzi A, Bellavia S, Dentali F, Frisullo G, Pitocco D, et al.
Res Pract Thromb Haemost
. 2024 Dec;
8(8):102623.
PMID: 39698184
Background: Serum thromboxane B (sTXB) is a validated biomarker of low-dose aspirin pharmacodynamics. In the original method, nonanticoagulated blood samples must be incubated at 37 °C immediately after withdrawal, centrifuged...
5.
Jeppsson A, Rocca B, Kaski J, Hansson E, Gudbjartsson T, James S, et al.
Eur J Cardiothorac Surg
. 2024 Oct;
67(1.
PMID: 39385505
No abstract available.
6.
Dobrev D, Rocca B, Kaski J
Eur Heart J Cardiovasc Pharmacother
. 2024 Sep;
10(7):571.
PMID: 39349995
No abstract available.
7.
Rocca B, Bigagli E, Cerbai E
Cardiovasc Drugs Ther
. 2024 Sep;
38(6):1103-1109.
PMID: 39348077
Polypharmacy is often necessary in complex, chronic, comorbid and cardiovascular patients and is a known risk factor for potential drug-drug interaction (DDI) that can cause adverse reactions (toxicity or therapeutic...
8.
Gigante B, Tamargo J, Agewall S, Atar D, Berg J, Campo G, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Sep;
10(7):614-645.
PMID: 39237457
Obesity and underweight are a growing health problem worldwide and a challenge for clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis and/or bleeding. This clinical consensus statement...
9.
Levy J, Shaw J, Castellucci L, Connors J, Douketis J, Lindhoff-Last E, et al.
J Thromb Haemost
. 2024 Jul;
22(10):2889-2899.
PMID: 39029742
The currently approved direct oral anticoagulants (DOACs) are increasingly used in clinical practice. Although serious bleeding risks are lower with DOACs than with vitamin K antagonists, bleeding remains the most...
10.
Rocca B, Tosetto A, Petrucci G, Rossi E, Betti S, Soldati D, et al.
Am J Hematol
. 2024 Jun;
99(8):1462-1474.
PMID: 38877813
Patients with essential thrombocythemia (ET) are treated with once-daily low-dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short-term Aspirin Regimens in EsSential Thrombocythemia...